NuvOx Pharma has completed a licensing agreement with the University of Pittsburgh for a patent application entitled, “Treatment of Acute Complications of Sickle Cell Disease.”
NuvOx Pharma has completed a licensing agreement with the University of Pittsburgh for a patent application entitled, “Treatment of Acute Complications of Sickle Cell Disease.” Inventors on the patent are Evan Unger, MD, David Wilson, PhD, both from NuvOx, and Solomon Ofori-Acquah, PhD, from the University of Pittsburgh.
Under the terms of this agreement NuvOx will have exclusive rights to develop a novel nanotechnology product for treatment of acute complications related to Sickle Cell Disease. Sickle Cell Disease is a genetic blood disorder affecting an estimated 100,000 Americans and millions of people worldwide. It disrupts the function of multiple organ systems, and often leads to acute crises that can be life-threatening.
According to Dr. Unger, CEO of NuvOx, “The preliminary data has shown great potential efficacy in treatment of Acute Chest Syndrome in transgenic Sickle Cell Disease mice in Dr. Ofori-Acquah’s lab, which is an acknowledged model for complication of the human disease. Mechanistically, the product should also have efficacy in vaso-occlusive painful crisis, which is the hallmark of this human disorder. Under the terms of this agreement, NuvOx shall have exclusive rights to develop the technology for Sickle Cell Disease.” In addition, Dr. Unger added, “Acute complications of Sickle Cell Disease contribute to major health care problems that are not only very costly, but also cause substantial pain and morbidity in patients with Sickle Cell Disease. We are committed to developing our technology to improve the quality of life in patients with this disease who have few, or no other options.”
About NuvOx Pharma
NuvOx Pharma is a biotechnology company based in Tucson, Arizona with a novel patent portfolio allowing it to develop an innovative nanotechnology platform including dodecafluoropentane (DDFP)-based oxygen therapeutics to treat a host of human conditions. Founded in 2008, NuvOx Pharma has demonstrated therapeutic feasibility in radiation-resistant cancer, hemorrhagic shock, traumatic brain injury, myocardial infarction, retinopathy and stroke. For additional information refer to http://www.nuvoxpharma.com.